SLU-PP-332 – 10mg

All products are for laboratory research purposes only. Not for human consumption, medical, or veterinary use. ION Peptides does not condone or support the use of peptides outside of controlled scientific research. By purchasing, you acknowledge that you are a qualified researcher or institution. You must be 21 or older.

Category Uncategorized

SLU-PP-332 (10 mg)

Research-Grade ERR Agonist Peptide/Small Molecule
Tagline: Metabolic & Mitochondrial Research Tool

Product Description

SLU-PP-332 is a synthetic agonist of the Estrogen‑Related Receptor alpha (ERRα) (and related ERRβ/γ) nuclear receptors. It has emerged as a tool in research for exploring mitochondrial biogenesis, energy metabolism, fat oxidation, and “exercise mimetic” pathways. In its 10 mg vial format, SLU-PP-332 is intended for laboratory and in vitro/preclinical research only—not for human use.

For laboratory and scientific research only. Not for human consumption.

Why Researchers Choose SLU-PP-332

Targets ERR α/β/γ – key regulators of mitochondrial and oxidative metabolism
Mimics physiological adaptations to endurance exercise in preclinical models
Supports research into metabolic syndrome, adiposity, insulin sensitivity
Useful for mitochondrial function, muscle fiber adaptation, fat oxidation studies
Supplied in high-purity form suitable for research protocols

Important Note

For laboratory and scientific research only. Not for human consumption, therapeutic or diagnostic use.

Compound Name	SLU-PP-332
Form	Lyophilized powder
Intended Research Use	Mitochondrial biogenesis, fat oxidation, metabolic regulation
Storage Conditions	–20 °C (dry); handle under inert conditions after reconstitution

Research Applications

Metabolic Regulation & Exercise-Mimetic Studies

SLU-PP-332 has been shown in preclinical models to activate ERR pathways, increase mitochondrial biogenesis (via PGC-1α activation), enhance energy expenditure, and promote fatty acid oxidation, mimicking some effects of endurance exercise without physical training.

Fat Oxidation & Adiposity Reduction

Animal studies indicate SLU-PP-332 may reduce adipose mass, increase resting metabolic rate, and improve insulin sensitivity, making it relevant for research into obesity, metabolic syndrome and related pathologies.

Mitochondrial & Cellular Bioenergetics Research

By targeting ERR receptors, SLU-PP-332 is used in research to probe mitochondrial function, oxidative phosphorylation, and the adaptation of skeletal muscle toward more oxidative (fat‐burning) fiber types.

References

Eissa ME. (2025). “SLU-PP-332 AND RELATED ERRα AGONISTS: A FOCUSED MINIREVIEW OF METABOLIC REGULATION AND THERAPEUTIC POTENTIAL.” UJPR.
https://doi.org/10.22270/ujpr.v10i3.1355
Nasri H. (2024). “New hopes on ‘SLU-PP-332’ as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view.” Journal of Renal Endocrinology.
https://doi.org/10.34172/jre.2024.25143
Mahale BM, Girase AM, Mahale M. (2024). “Unlocking the potential: SLU-PP-332 and the future of exercise enhancement and metabolic health.” Research Journal of Science and Technology, 16(4):321-4. https://doi.org/10.52711/2349-2988.2024.00047
“A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” (2023). J Pharmacol Exp Ther.
https://doi.org/10.1124/jpet.123.001733

Mechanism of Action

ERRα/β/γ Agonism: Binds to estrogen-related orphan receptors, triggering transcription of genes for mitochondrial biogenesis, oxidative metabolism, and fat oxidation.
PGC-1α Activation: Upregulates PGC-1α (co-activator) leading to increased mitochondrial number and function.
Fatty Acid Oxidation Enhancement: Upregulates enzymes such as CPT1 and MCAD, enhances fat utilization for energy.
Exercise‐Mimetic Adaptation: Induces muscle fiber type shift toward oxidative fibers, increased endurance/mitochondrial density.
Energy Expenditure Increase: Elevates resting metabolic rate, thermogenesis and substrate use in preclinical models.

References

Eissa ME. (2025). “SLU-PP-332 AND RELATED ERRα AGONISTS: A FOCUSED MINIREVIEW OF METABOLIC REGULATION AND THERAPEUTIC POTENTIAL.” UJPR.
https://doi.org/10.22270/ujpr.v10i3.1355
Nasri H. (2024). “New hopes on ‘SLU-PP-332’ as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view.” Journal of Renal Endocrinology.
https://doi.org/10.34172/jre.2024.25143
Mahale BM, Girase AM, Mahale M. (2024). “Unlocking the potential: SLU-PP-332 and the future of exercise enhancement and metabolic health.” Research Journal of Science and Technology, 16(4):321-4. https://doi.org/10.52711/2349-2988.2024.00047
“A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” (2023). J Pharmacol Exp Ther.
https://doi.org/10.1124/jpet.123.001733